Skip to main content

Advertisement

Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer

Fig. 2

Kaplan–Meier survival analysis of overall survival of CRC patients with EGFR, HER2, c-MYC, and MET GCN changes, which were defined according to the following criteria: a, d, g, j amplification; b, e, h, k GCN gain and c, f, i, l ASCO/CAP criterion

Back to article page